Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.56 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27857193 | 0.86 | GRM2 (0.59) | RECQLGRM2TSHRPKMHTT | |
| SCHEMBL1169685 | 0.83 | RECQL (0.60) | RECQLGRM2MPOTSHRMAPT | |
| SCHEMBL4792406 | 0.83 | RECQL (0.60) | RECQLGRM2MPOTSHRMAPT | |
| SCHEMBL16475156 | 0.82 | RECQL (0.54) | RECQLGRM2TSHRMAPTSLC9A1 | |
| SCHEMBL1172524 | 0.82 | RECQL (0.58) | RECQLGRM2MPOTSHRMAPT | |
| SCHEMBL9941798 | 0.81 | RECQL (0.50) | RECQLGRM2MPOTSHRMAPT | |
| SCHEMBL15687378 | 0.80 | RECQL (0.55) | RECQLGRM2MPOTSHRMAPT | |
| SCHEMBL18070761 | 0.79 | GRM2 (0.51) | RECQLGRM2SLC9A1LMNAHPGD | |
| SCHEMBL27745777 | 0.79 | GRM2 (0.37) | RECQLGRM2 | |
| SCHEMBL24134933 | 0.79 | SLC9A1 (0.44) | RECQLGRM2SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024006781-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-8519186-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype 1 (VR1) receptors | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519186-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype 1 (VR1) receptors | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519186-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype 1 (VR1) receptors | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| CN-102775350-A | Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (VR1) receptors | ABBOTT LAB | 2012-11-14 | — | — | CN | disclosed |
| EP-2012779-B1 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LAB (US) | 2012-05-16 | — | — | EP | disclosed |
| CN-101466374-B | Methods for preparing indazolyl ureas that inhibit vanilloid subtype 1(VR1) receptor | ABBOTT LAB | 2012-03-21 | — | — | CN | disclosed |
| CN-102321025-A | Preparation suppresses the method for the indazolyl urea of vanilloid subtype type 1 (VR1) acceptor | ABBOTT LAB | 2012-01-18 | — | — | CN | disclosed |
| US-7847104-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype1 (VR1) receptors | ABBOTT LABORATORIES (US) | 2010-12-07 | — | — | US | disclosed |
| US-7847104-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype1 (VR1) receptors | ABBOTT LABORATORIES (US) | 2010-12-07 | — | — | US | disclosed |
| US-7847104-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype1 (VR1) receptors | ABBOTT LABORATORIES (US) | 2010-12-07 | — | — | US | disclosed |
| CN-101466374-A | Methods for preparing indazolyl ureas that inhibit vanilloid subtype 1(VR1) receptor | ABBOTT LAB (US) | 2009-06-24 | — | — | CN | disclosed |
| EP-2012779-A2 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | Abbott Laboratories (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007121339-A2 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LABORATORIES (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007121339-A2 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LABORATORIES (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | ABBVIE INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | ABBVIE INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | ABBVIE INC. | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | RECQL 3036/4885GRM2 273/4885MPO 2339/4885 |
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | UTS2R, VIPR1, VRK1 | RECQL 4196/4885GRM2 1382/4885MPO 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.